The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
63
Panhandle Research and Medical Clinic
Gulf Breeze, Florida, United States
Conquest Research LLC - Winter Park - ClinEdge - PPDS
Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions
Cumulative number will be measured by magnetic resonance imaging (MRI) scans.
Time frame: 12 Weeks
Cumulative Number of Total Number of T1 GdE Lesions
Cumulative number will be measured by MRI scans.
Time frame: 12 Weeks
Cumulative Number of New and/or Enlarging T2 Lesions
Cumulative number will be measured by MRI scans.
Time frame: 12 Weeks
Pharmacokinetics (PK): Plasma Trough Concentrations of LY3541860
Plasma trough concentrations of LY3541860 was measured.
Time frame: Baseline Through Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Winter Park, Florida, United States
Consultants in Neurology
Northbrook, Illinois, United States
Sharlin Health and Neurology
Ozark, Missouri, United States
Premier Neurology
Greer, South Carolina, United States
Hope Neurology
Knoxville, Tennessee, United States
Centre Hospitalier Intercommunal - Site de Poissy
Poissy, France
Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta-VIA MANGIAGALLI 3
Milan, Italy
Pauls Stradins Clinical Univeristy Hospital
Riga, Latvia
Neurocentrum Bydgoszcz sp. z o.o.
Bydgoszcz, Poland
...and 10 more locations